- Home
- TCBS vs ACRV Comparison
TCBS vs ACRV Comparison
Compare TCBS & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBS | ACRV |
|---|---|---|
| Founded | 1934 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0M | 52.4M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TCBS | ACRV |
|---|---|---|
| Price | $17.10 | $1.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 2.0K | ★ 602.8K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 327.27 | 15.13 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | $17.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.01 | $1.05 |
| 52 Week High | $20.00 | $3.56 |
Technical Indicators
Market Signals| Indicator | TCBS | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 50.01 |
| Support Level | $15.70 | $1.49 |
| Resistance Level | $18.21 | $1.86 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 38.78 | 67.86 |
Price Performance
Historical ComparisonAbout TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.